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allogeneic transfusion ($1512), autologous ($1899) and allogeneic transfusion
($1906) with differences persisting in sensitivity analyses. Cell salvage resulted in
net savings at a threshold of $556/patient. CONCLUSIONS:Use of CS, particularly
with autologous blood pre-donation appears cost-saving and cost-effective in pe-
diatric surgery and should be encouraged.
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OBJECTIVES: Surgical site infections (SSIs) associated with total knee arthroplasty
(TKA) have a significant negative impact on outcomes and hospital reimburse-
ment. Our study uniquely looks at the impact of patients having SSI in their initial
admissionwith downstream outcomes of readmission to assess the complete con-
sequences of TKA related SSI, beyond a single episode of care. METHODS: Thom-
son Medstat Marketscan® Database was used to identify patients having a TKA
(ICD9-CM procedure code 81.54) between January 2007 and December 2009. Pa-
tients experiencing infections were defined by ICD-9-CM codes 998.5x, 998.66 and
998.67 as their secondary diagnosis in their index admission and as their primary or
secondary diagnoses during their 90-day readmissions. Total SSI burden was as-
sessed by evaluating differences in length of stay (LOS) and costs relative to those
with no SSI in the 3 groups: 1) during the initial admission in patients developing
SSI; 2) during the 90-day post surgery for patients who had developed SSI in their
initial admission; and 3) in patients experiencing SSI in their postoperative period.
Generalized linear models adjusting for age, gender, region and p/a diabetes were
used to compute mean differences and 95% confidence intervals. RESULTS: Pa-
tients in group 1 developing SSI as a complication of TKA incur an additional LOS of
2.4 days (95%CI:2.2-2.6 days) and an extra $6360 costs (95%CI:$4610-$8100). Group 2
patients are at risk of 0.75more downstream readmissions, and incur an average of
0.51 days additional LOS (95%CI:0.17-0.85) and $1,160 additional payments (95%CI:
$130-$2180). Group 3 patients are at risk of 1.3 additional readmissions, and incur
an average additional LOS of 8.2 days (95%CI:8.0-8.4) and $21,830 (95%CI:$21,160-
$22,510) in additional payments. CONCLUSIONS: SSI associated with TKA in-
creases current and downstream burden by a factor of 1.3-8.0 times in terms of
readmission rates and additional LOS and provider payments.
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OBJECTIVES: Solid organ transplants (SOT) are expensive, and much of the cost is
incurred in the first 3 months of care to cover pre-transplant, procurement and pro-
cedural costs, which can reach $200,000 per transplant, and higher with complica-
tions. Delayed graft function (DGF) is a complication affecting 20-40% of kidney trans-
plants and is believed to result from ischemic reperfusion injury (IRI). The objective of
this analysis is to quantify the additional charges and length of stay (LOS) associated
with complications such as DGF. METHODS: Using 2008 Health Care Utilization
Project (HCUP) data, individuals with a recorded transplant procedure (ICD-9 CM:
07.94 (thymus); 33.50-33.52 (lung); 336 (heart-lung); 41.94 (spleen); 46.97 (intestine);
50.51 and 50.59 (liver); 52.80-52.83 (pancreas); 65.92 (ovary) were identified. The
mean hospital charges for individuals with and without a recorded complication
diagnosis (ICD-9 CM 996.80-996.89 and additionally for kidney patients a recorded
dialysis procedure 39.95) were compared using student’s t-test. RESULTS: The
number of SOTs (and complications) for eachorgan typewere: 4119 (21%) kidney, 1677
(17%) liver, 485 (28%) heart, and 264 (35%) lung. Heart-lung, intestine, pancreas and
spleenwere excluded from the analysis with100 transplants each. Kidney and liver
transplant patients with complications had significantly higher mean hospital
charges and LOS than thosewithout the complications: kidney ($209,503 vs. $160,997,
p0.001) and (7.0daysvs. 11.1days, p0.001), and liver ($460,351vs. $340,296, p0.001)
and (21.0 days vs. 31.6 days). Heart and Lung transplant patients had higher charges
than those without the complication diagnosis. The difference was not statistically
significant. CONCLUSIONS: Our results demonstrate that having to treat complica-
tions of transplants adds significantly to the cost of hospital care and LOS. There is
a need for a novel agent that may reduce IRI. Proactive management of patients
with risk of IRI may confer substantial savings to hospitals.
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OBJECTIVES: Evaluate the cost of care for patients undergoing posterolateral spinal
fusion (PLF) between on-label Si-CaP use and off-label rhBMP-2 use. It is hypothe-
sized that Si-CaP patients will have lower Total patient costs (cost of entire inpa-
tient hospitalization), lower supply costs, and lower Operating Room costs.
METHODS: Patients over age 18 having a PLF procedure (ICD9 codes 81.62, 81.63, or
81.64) and receiving Si-CaP or rhBMP-2 on day of procedure between January, 2006
and December 31, 2010 were selected. Comorbidities were identified using a mod-
ified Charlsonmethod. Patients with 9 ormore levels fused were excluded. Univar-
iate group comparisons weremade using chi-square and student t-tests. Multivar-
iate linear models were developed using both normal and log transformation.
Discharges with costs less than $1,000 or greater than $500,000 were excluded in
the normal multivariate models but were included in the log transformed models.
RESULTS: A total of 60,260 patients were initially identified. After applying exclu-
sion criteria 59,229 patients were available for analysis (98.3%). Univariate compar-
isons of Total Cost as well as OR and Supply costs were significantly lower for the
Si-CaP cohort (p  0.05). Adjusting for patient and hospital covariates also showed
statistically significant lower estimated mean costs for Si-CaP for all outcomes (p
0.001). Differences in estimatedmeans for Total Costswere lower for Si-CaP $8931
and $7582 using normal and log-transformed values respectively. Estimatedmeans
for Supply Costs showed similar results of $7255 and $5274 for normal and log-
transformed values respectively. Operating RoomCostswere also similar, $961 and
$809. CONCLUSIONS: After adjusting for patient and hospital covariates Si-CaP
patients had significantly lower Total Patient Costs. While Supply Costs showed
similar results they do not fully explain the reduction in Total Cost suggesting that
there are other cost advantages besides product acquisition cost. Further research
should consider cost of complications and readmission.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in prostate surgery patients with perioperative blood loss (PBL) to those who
did not experience perioperative blood loss (NPBL). METHODS: Males with inpa-
tient prostate surgery discharges (ICD-9-CM: 60.0, 60.12, 60.14, 60.15, 60.3, 60.5,
60.6X, 60.72, 60.73, 60.79, 60.8X, 60.93, 60.94) were identified from the Premier Per-
spective® Database (CY 2009 - Q2 of CY 2010). Discharges were categorized into the
PBL group if they had received at least one blood transfusion (ICD-9-CM: 99.02-
99.07; CPT: 36430, 35455) during the hospital stay, otherwise were included in the
NPBL group. Blood transfusionwas assumed to be an indicator for PBL. Groupswere
matched (1:1) on age, race and APR-DRG severity using propensity scores. Adjusted
estimates for costs (total and departmental), days of stay in hospital (LOS), ICU, and
operating room (OR) time in minutes were compared between the PBL and NPBL
groups using generalized linearmodel (GLM)with gamma distribution and log link.
RESULTS: A total of 18,681prostate surgery discharges were identified. Of those,
1176 (6.3%) required at least one blood transfusion perioperatively. Aftermatching,
1168 discharges were retained in each group for the final analysis. Adjusted mean
total costs were significantly higher for the PBL group compared to NPBL group
($16,757 vs. $12,712, p0.0001). Mean adjusted costs associated with room& board,
surgery and pharmacy between PBL and NPBL group and were also significantly
higher for the PBL group (all p0.05). Compared to the NPBL group, the PBL group
had higher mean LOS (5.8 days vs. 3.6 days), and longer OR time (232 minutes vs.
211 minutes) (both p0.05). CONCLUSIONS: Perioperative blood loss for prostate
surgery patients adds significant burden to hospital costs and resources. Adopting
strategies aimed at minimizing PBL during prostate surgery process may conserve
valuable medical resources.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in renal surgery patientswith perioperative blood loss (PBL) to thosewho did
not experience perioperative blood loss (NPBL).METHODS: Inpatient discharges for
renal surgery (ICD-9-CM:55.0X, 55.1X, 55.24, 55.3X-55.8X) were identified from the
Premier Perspective® Database (CY 2009-Q2 of CY 2010). Discharges were catego-
rized as PBL group if they had received at least one blood transfusion (ICD-9-CM:
99.02-99.07; CPT:36430, 35455) during the hospital stay, otherwise were included in
the NPBL group. Blood transfusion was assumed to be an indicator for PBL. Groups
were matched (1:1) on age, gender, race, CCI score, APR-DRG severity and elective
admission type using propensity score. Adjusted estimates for costs (total and
departmental), days of stay in hospital (LOS), ICU, and operating room (OR) time in
minutes were compared between PBL and NPBL groups using generalized linear
model (GLM)with gammadistribution and log link. RESULTS:A total of 27,573 renal
surgery discharges were identified. 4,885 (17.7%) of all the selected patients re-
quired at least one blood transfusion perioperatively. After matching, 4,699 dis-
chargeswere retained in each group for the final analysis. Adjustedmean total cost
were significantly higher for the PBL group compared to NPBL group ($48,583 vs.
$35,298, p0.0001). Mean adjusted costs associated with room & board, central
supply, surgery, pharmacy and laboratory and pathology between PBL and NPBL
group and were also significantly higher for PBL group (all p0.05). Compared to
NPBL group, PBL group had higher mean LOS (10.5 days vs. 7.9 days) and ICU days
(4.5 days vs. 3.6 days) and had longer OR time (227 minutes vs. 194 minutes) (all
p0.0001). CONCLUSIONS: Perioperative blood loss for renal surgery patients adds
significant burden to hospital costs and resources. Adopting strategies aimed at
minimizing perioperative blood loss during renal surgeries may be helpful.
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